Role of meditation in reducing sympathetic hyperactivity and improving quality of life in lupus nephritis patients with chronic kidney disease

Journal of the Medical Association of Thailand

Volumn 97, Issue 3 SUPPL. 3, 2014, Pages

  Bantornwan, Sirawit ^a   Watanapa, Wattana B ^a   Hussarin, Poungpetch ^a   Chatsiricharoenkul, Somruedee ^a   Larpparisuth, Nuttasith ^a   Teerapornlertratt, Tanyarat ^a   Vareesangthip, Jutamas ^b   Vareesangthip, Kriengsak ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Graduate School   (Thailand)

Author keywords

Chronic kidney disease; Heart rate variability; Meditation; Normetanephrine; Quality of life; Sympathetic hyperactivity

Indexed keywords

CYCLOPHOSPHAMIDE; NORMETADRENALIN;

ADULT; AGED; ARTICLE; AUTONOMIC DYSFUNCTION; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOURIER TRANSFORMATION; HEART RATE VARIABILITY; HUMAN; HYPERACTIVITY; LIQUID CHROMATOGRAPHY MASS SPECTROMETRY; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MASS SPECTROMETRY; MEDITATION; PILOT STUDY; PROSPECTIVE STUDY; QUALITY OF LIFE; RESPIRATION CONTROL; SHORT FORM 36; SYMPATHETIC TONE; ADRENERGIC SYSTEM; BLOOD; CHRONIC KIDNEY FAILURE; HEART RATE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; YOUNG ADULT;

ADULT; AGED; FEMALE; HEART RATE; HUMANS; LUPUS NEPHRITIS; MALE; MEDITATION; MIDDLE AGED; NORMETANEPHRINE; PROSPECTIVE STUDIES; QUALITY OF LIFE; RENAL INSUFFICIENCY, CHRONIC; SYMPATHETIC NERVOUS SYSTEM; YOUNG ADULT;

EID: 84900023616     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Harle P, Straub RH, Wiest R, Mayer A, Scholmerich J, Atzeni F, et al. Increase of sympathetic outflow measured by neuropeptide Y and decrease of the hypothalamic-pituitary-adrenal axis tone in patients with systemic lupus erythematosus and rheumatoid arthritis: another example of uncoupling of response systems. Ann Rheum Dis 2006; 65: 51-6.
2. Louthrenoo W, Ruttanaumpawan P, Aramrattana A, Sukitawut W. Cardiovascular autonomic nervous system dysfunction in patients with rheumatoid arthritis and systemic lupus erythematosus. QJM 1999; 92: 97-102.
3. Aydemir M, Yazisiz V, Basarici I, Avci AB, Erbasan F, Belgi A, et al. Cardiac autonomic profile in rheumatoid arthritis and systemic lupus erythematosus. Lupus 2010; 19: 255-61.
4. Schlaich MP, Socratous F, Hennebry S, Eikelis N, Lambert EA, Straznicky N, et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol 2009; 20: 933-9.
5. Jevning R, Wallace RK, Beidebach M. The physiology of meditation: a review. A wakeful hypometabolic integrated response. Neurosci Biobehav Rev 1992; 16: 415-24.
6. Infante JR, Torres-Avisbal M, Pinel P, Vallejo JA, Peran F, Gonzalez F, et al. Catecholamine levels in practitioners of the transcendental meditation technique. Physiol Behav 2001; 72: 141-6.
7. Hjemdahl P, Fagius J, Freyschuss U, Wallin BG, Daleskog M, Bohlin G, et al. Muscle sympathetic activity and norepinephrine release during mental challenge in humans. Am J Physiol 1989; 257: E654-64.
8. Curiati JA, Bocchi E, Freire JO, Arantes AC, Braga M, Garcia Y, et al. Meditation reduces sympathetic activation and improves the quality of life in elderly patients with optimally treated heart failure: a prospective randomized study. J Altern Complement Med 2005; 11: 465-72.
9. Chandra P, Sands RL, Gillespie BW, Levin NW, Kotanko P, Kiser M, et al. Predictors of heart rate variability and its prognostic significance in chronic kidney disease. Nephrol Dial Transplant 2012; 27: 700-9.
10. Leurmarnkul W, Meetam P. Properties testing of the retranslated SF-36 (Thai version). Thai J Pharm Sci 2005; 29: 69-88.
11. Vareesangthip J. The improvement of the quality of life of the end stage renal disease patients by Dhamma practice. Graduate School, Mahachulalongkorn-rajavidyalaya University. Bangkok: Amy Enterprise; 2010.